Title
Structural characterization of the HSP70 interaction domain of the hepatitis C viral protein NS5A

Permalink
https://escholarship.org/uc/item/91h66262

Authors
Khachatoorian, Ronik
Ruchala, Piotr
Waring, Alan
et al.

Publication Date
2014-11-25

Peer reviewed
Structural characterization of the HSP70 interaction domain of the hepatitis C viral protein NS5A

Ronik Khachatooorian a,1, Piotr Ruchala b,1, Alan Waring c, Chun-Ling Jung d, Ekambaram Ganapathy a, Nicole Wheatley e,f, Christopher Sundberg g, Vaithilingaraja Arumugaswami h,1, Asim Dasgupta i,j,l,m, Samuel W. French a,k,l,m

a Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
b Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
c Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
d Department of Basic Sciences and Oncology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
e Division of Molecular Medicine at the Department of Medicine, Los Angeles County Harbor-UCLA Medical Center, Torrance, CA, United States
f Departamento de Microbiologia, Immunologia, e Parasitologia, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
g Department of Surgery, The Board of Governors Regenerative Medicine Institute at Cedars-Sinai Medical Center, Los Angeles, CA, United States
h Department of Human Genetics, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
i Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
j UCLA AIDS Institute, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
k Molecular Biology Institute, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
l Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, CA, United States
m UCLA AIDS Institute, David Geffen School of Medicine at University of California, Los Angeles, CA, United States

A R T I C L E   I N F O

Article history:
Received 8 September 2014
Returned to author for revisions 2 October 2014
Accepted 15 October 2014
Available online 25 November 2014

Keywords:
Peptide
HSP70
NS5A
HCV
Protein binding
IRES

A B S T R A C T

We previously identified the NS5A/HSP70 binding site to be a hairpin moiety at C-terminus of NS5A domain I and showed a corresponding cyclized polyarginine-tagged synthetic peptide (HCV4) significantly blocks virus production. Here, sequence comparison confirmed five residues to be conserved. Based on NS5A domain I crystal structure, Phe171, Val173, and Tyr178 were predicted to form the binding interface. Substitution of Phe171 and Val173 with more hydrophobic unusual amino acids improved peptide antiviral activity and HSP70 binding, while similar substitutions at Tyr178 had a negative effect. Substitution of non-conserved residues with arginines maintained antiviral activity and HSP70 binding and dispensed with polyarginine tag for cellular entry. Peptide cyclization improved antiviral activity and HSP70 binding. The cyclic retro-inverso analog displayed the best antiviral properties. FTIR spectroscopy confirmed a secondary structure consisting of an N-terminal beta-sheet followed by a turn and a C-terminal beta-sheet. These peptides constitute a new class of anti-HCV compounds.

© 2014 Elsevier Inc. All rights reserved.

Abbreviations: Ac, acetyl group; 2Nal, 2-naphthylalanine; Ahx, 6-aminohexanoic acid; Bip, 4,4'-biphenylalanine; C34, C terminal 34 amino acids of NS5A domain I; Cha, cyclohexylalanine; Chg, cyclohexylglycine; CysNH, reduced cysteine; CysRS, S-tet-butyl-cysteine; DAA, direct acting antiviral; Dpa, 3,3'-diphenylalanine; DMSO, dimethyl sulfoxide; EDT, ethanedithiol; Fmoc, 9-fluorenylmethylloxycarbonyl; FTIR, Fourier transform infrared (spectroscopy); HBD, HSP binding domain; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HCVcc, HCV cell culture; HIP, HSP interfering peptide; HSP, heat shock protein; IC50, half-maximal inhibition concentration; IRES, internal ribosomal entry site; MALDI-MS, matrix-assisted laser desorption ionization mass spectrometry; MBP, maltose binding protein; NBD, nucleotide binding domain; NCR, noncoding region; NS, nonstructural; NS5A, nonstructural protein 5A; Pal, palmitic acid; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PEGIFN, pegylated interferon-α; RBV, ribavirin; RLuc, Renilla luciferase; RPLHC, reverse-phase high performance liquid chromatography; SBD, substrate binding domain; SPR, surface plasmon resonance; SVR, sustained virological response; TIS, thiainosile

* Corresponding author at: Department of Pathology and Laboratory Medicine, UCLA Center for Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095-1732, United States. Tel.: +1 310 267 2795; fax: +1 310 267 2058.

E-mail addresses: RKhch@ucla.edu (R. Khachatooorian), PRuchala@mednet.ucla.edu (P. Ruchala), AWaring@mednet.ucla.edu (A. Waring), CLJung@mednet.ucla.edu (C.-L. Jung), GEkambaram@ucla.edu (E. Ganapathy), Wheatley.NM@gmail.com (N. Wheatley), Christopher.Sundberg@gmail.com (C. Sundberg), Vaithil.Arumugaswami@chhs.org (V. Arumugaswami), Dasgupta@ucla.edu (A. Dasgupta), SFrench@mednet.ucla.edu (S.W. French).

1 These authors equally contributed to this work.

http://dx.doi.org/10.1016/j.virol.2014.10.011
0042-0196/© 2014 Elsevier Inc. All rights reserved.
The hepatitis C virus (HCV) infects 3% of the world population and is mainly responsible for liver transplantation in patients with cirrhosis in developed countries (Sheppard et al., 2005). Furthermore, HCV is the most common chronic blood borne pathogen in the United States (U.S.) affecting 1.8% of the population and is the major etiologic factor responsible for the recent doubling of hepatocellular carcinoma (HCC) (El-Serag, 2002).

Recently HCV infection has been treated with a combination of pegylated interferon-α (PEG-IFN), ribavirin (RBV) and NS3/4A protease inhibitors which have improved sustained virological response (SVR) from PEG-IFN and RBV alone, but also increased adverse side effects including anemia and gastrointestinal symptoms (Ciesek and Manns, 2011). In December of 2013 sofosbuvir which targets the viral polymerase was FDA approved in combination with PEG-IFN and RBV and showed very high efficacy (at least 90% in clinical trials) but at great cost $84,000–$168,000. Efficacy and adverse events outside clinical trials remain to be evaluated. There is optimism that a combination of direct acting antivirals (DAAs) may eliminate the need for PEG-IFN and RBV, the major culprits responsible for significant side effects. However, DAAs can result in resistant virus as targeting viral proteins puts direct selective pressure for resistant mutants. Therefore, there is still a need for new compounds to use in drug cocktails to improve efficacy, avert resistance, reduce cost, and reduce adverse events.

HCV is an RNA virus classified in the genus Hepacivirus in the Flaviviridae family. It possesses an approximately 9.6 kb positive sense RNA genome that is translated as a single polypeptide approximately 3000 amino acids in length (Baron, 1996; Lindenbach and Rice, 2005). It is subsequently proteolytically cleaved into 10 viral proteins including the structural proteins Core, E1, E2, and the integral membrane ion channel p7, as well as the non-structural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B (Lindenbach and Rice, 2005). The 5’ non-coding region (NCR) of the viral genome possesses an internal ribosomal entry site (IRES) (Wang et al., 1993), a cis-acting element found in some host RNA transcripts as well as in viruses that allows ribosomal translation initiation to occur internally within a transcript in lieu of 5’ cap dependent translation (Pacheco and Martinez-Salas, 2010). The HCV viral life cycle in a cell can be divided into six phases: 1) binding and internalization, 2) cytoplasmic release and uncoating, 3) viral polyprotein translation and processing, 4) RNA genome replication, 5) packaging and assembly, and 6) virus morphogenesis and secretion (Moradpour et al., 2007). NS5A, a 56–59 kDa multifunctional phosphoprotein, is a component of the viral replicase complex and has been implicated in regulation of HCV genome replication, IRES-mediated viral protein translation, virion assembly, and infectious virion secretion (He et al., 2003; Hughes et al., 2009; Khachatoorian et al., 2012a, 2012b; Tellingshusen et al., 2008).

Interestingly, cellular heat-shock proteins (HSPs) also play an important role in the replication of RNA viruses (Vasconcelos et al., 1998; Weeks and Miller, 2008; Zheng et al., 2010). HSPs, which normally assist unfolded or misfolded polypeptide chains to (re) fold into functional proteins, are crucial for cell survival during stressful conditions (Mayer and Bukau, 2005). We have previously identified, through co-immunoprecipitation and subsequent mass spectrometric analyses, an NS5A/HSP complex composed of NS5A, HSP70, and HSP40 (cofactor of HSP70) and demonstrated their co-localization in Huh-7 cells (Gonzalez et al., 2009). We further showed that both NS5A-augmented IRES-mediated translation and virus production are blocked by 1) HSP70 knockdown, 2) the HSP synthesis inhibitor quercetin, a bioflavonoid, and 3) a small hairpin peptide (HCV4) from NS5A domain I that is capable of blocking NS5A/HSP70 interaction, with no associated cytotoxicity (Gonzalez et al., 2009; Khachatoorian et al., 2012a, 2012b). These findings support our hypothesis that HCV utilizes an NS5A/HSP complex for the IRES-mediated translation of its genome.

The HCV4 hairpin peptide described previously (Khachatoorian et al., 2012b) is a potent small molecule inhibitor of virus specific NS5A-driven IRES-mediated translation of the viral genome and is also capable of disrupting the NS5A/HSP70 complex formation in vitro. This peptide was identified by deletion analyses of NS5A which narrowed down the site of NS5A/HSP70 interaction to the C terminal 34 amino acids of NS5A domain I (C34) followed by alanine scanning mutagenesis on the C34 region. These analyses identified the NS5A/HSP70 binding region on NS5A to be the hairpin moiety at C34 hereafter referred to as the HSP binding domain (HBD). Subsequently, we sought to further characterize the HBD site and identify the specific amino acid residues involved in this interaction, with the goal of generating peptides that would be even more potent than the HCV4 analog. We refer to these peptides as HSP interfering peptides (HIPs).

Results

Five amino acid residues are conserved in the HSP binding domain (HBD) of NS5A

HBD consists of 10 amino acids that form a beta-sheet structure at the C terminus of NS5A domain I (Fig. 1). Comparison of the H77 and Con1 sequences at the site of HBD revealed five conserved residues: Phe171, Val173, Gly174, Leu175, and Tyr178 (Table 1, highlighted in green). We hypothesized that these five residues may be critical for the NS5A/HSP70 interaction.

Fig. 1. Schematic representation of the HBD region (green) based on the previously reported crystal structure of dimeric NS5A domain I (Tellingshusen et al., 2005). (A) NS5A domain I dimer. (B) The HBD hairpin moiety shown at two different angles. The side chains of four conserved residues (Phe171, Val173, Leu175, and Tyr178) are also shown. (C) The HBD hairpin moiety showing four additional residues in blue (Thr170, Leu172, Cln177 and Leu179) that were substituted with arginine residues to enhance cell permeability of HCV peptides.
HSP70. We reasoned that Gly174 and Leu175 are necessary for a turn between the two beta-sheets of the hairpin and may, therefore, play a stabilizing role in the NS5A/HSP70 interaction consistent with the role of glycine and leucine in facilitating beta-turns. Based on these observations, we hypothesized that Phe171, Val173, and Tyr178 form the main binding motif and that certain residues at these positions affect peptide antiviral activity. Through computer assisted molecular modeling, we also reasoned that Gly174 may be substituted with D-Pro to facilitate a turn between the hairpin's two beta-sheets in order to help maintaining a hairpin-like structure. Thus, all the peptides generated for this study bear D-Pro instead of Gly at position 174 (except for the retro-inverso analog HCV18RI which bears an L-Pro at this position) (Table 1). Also Leu175 was substituted with the more hydrophobic cyclohexylalanine (Cha) (Table 1). We proceeded to generate groups of peptide derivatives of HCV4 with different modifications as described below, and all peptides were tested for their antiviral activity. Representative peptides from each group were further assayed to determine their dose response as well as their binding affinity. HCV1-3 were not tested for their antiviral activity in this study as they do not possess an arginine tag and, therefore, be incapable of cellular entry. However, we have previously reported an effective liposome-mediated delivery of HCV2 and HCV3 (Khachatoorian et al., 2012b). HCV1–3 were, nonetheless, tested for their structural conformation.

**Substitution of Phe171 and Val173 with more hydrophobic residues increases peptide antiviral activity and HSP70 binding affinity**

Based on the spatial arrangement of the Phe171, Val173, and Tyr178 residues, we hypothesized that substitutions within the synthetic hairpin peptides at these residues would affect their binding to HSP70 and, therefore, alter the antiviral activity of these peptides. All amino acid substitutions used were intended to increase the hydrophobicity of these residues as they possess larger hydrophobic side chains. To this end, we used L-2-naphthylalanine (2Nal) and L-3,3’-diphenylalanine (Dpa) as substituents for Phe171 and L-cyclohexylglycine (Chg) and S-tert-butyl-l-cysteine (CystBu) as substituents for Val173. All peptides bearing any of these modifications at Phe171 and/or Val173 are marked with the open triangle symbol △ in Tables 1–3 and Fig. 2. HCV9, HCV10, HCV11, HCV12, HCV15, and HCV18 indeed showed improved antiviral activity compared with the HCV4 peptide in the HCV cell culture (HCVcc) system (Fig. 2A).

We also determined the dose response of HCV10, HCV15, and HCV18 and showed that the IC50 of these peptides is lower compared with HCV4 (Table 1). In addition, we determined the HSP70 binding affinity of these peptides through surface plasmon resonance (SPR) analyses utilizing recombinant full-length HSP70 in fusion with N-terminal maltose binding protein (MBP) immobilized on the SPR chip. The HSP70 binding affinity of HCV10, HCV15, and HCV18 was found to be higher than that of HCV4 (Table 3).

**Substitution of Tyr178 with more hydrophobic residues decreases peptide antiviral activity and HSP70 binding affinity**

Tyr178 is a polar residue, and we hypothesized that substituting it with highly hydrophobic residues may impair the antiviral activity of the peptides. We utilized L-4,4’-biphenylalanine (Bip) or L-Dpa as substituents for Tyr178, and peptides bearing these analogs (HCV7, HCV8, HCV13, and HCV18) were tested for their structural conformation. As shown in Fig. 2A, these analogs (HCV7, HCV8, HCV13, and HCV18) showed decreased efficacy in blocking virus production in the cell culture system compared with HCV4.

**Table 1**

| Sequence and characterization of all peptides generated. The green highlights indicate the conserved amino acids. The red highlights indicate amino acid substitutions that resulted in peptides with better antiviral activity and higher HSP70 binding affinity compared to HCV4, while the blue highlights indicate lower antiviral activity and HSP70 binding affinity. Cyclization of the peptides is also emphasized by gray highlights at both the N and C termini. The symbols to left of the table refer to specific modifications to peptides: △ indicates substitution of Phe171 and/or Val173 with more hydrophobic residues; ▲ indicates addition of a lipid tag to the peptide; □ indicates the retro-inverso analog; ▪ indicates peptide linearization; and ▼ indicates decreasing the length of cyclizing linker achieved by a thioether linkage. Solid symbols indicate a beneficial modification (i.e. improved antiviral activity and HSP70 binding), while open symbols indicate a negative effect. (2-Nal = 2-naphthylalanine; -Ac = acetyl group; Ahx = 6-aminohexanoic acid; Bip = L-4,4’-biphenylalanine; Chg = cyclohexylglycine; Cys(Su) = reduced cysteine; Cy510 = S-tert-butyl-cysteine; Dpa = L-3,3’-diphenylalanine; Pal = palmitic acid). |
Substitution of the non-conserved amino acids with arginines enables membrane penetration without a polyarginine tag and maintains antiviral activity.

The HCV4 peptide consists of a polyarginine tag at its N-terminus which allows for cellular internalization (Table 1). Addition of this tag significantly increases the molecular weight of the peptide and may lead to cellular toxicity. The two beta-sheets of the hairpin structure include five non-conserved residues: Thr170, Leu172, Asn176, Gln177, and Leu179 (Fig. 1C, blue residues). As shown in Fig. 2A, peptides bearing arginines at these positions (HCV5–HCV15, HCV15R, HCV16, HCV18, and HCV18RI) maintained their antiviral activity compared to the HCV4 peptide, which indicates that they were capable of penetrating the plasma membrane. Furthermore, these peptides have the benefit of being significantly smaller. All the peptides in this study were generated without the polyarginine tag.

Addition of a lipid tag to the peptide does not interfere with its antiviral activity.

We also sought to determine whether conjugation of a lipid (e.g. palmitic acid) to the HCV5 peptide would interfere with its antiviral activity, and whether addition of a lipid tag would interfere with HCV70 binding. Solid symbols indicate a beneficial modification (i.e. improved antiviral activity and HSP70 binding), while open symbols indicate a negative effect. The data for 10 nM Phe171 and/or Val173 with more hydrophobic residues; ▲ indicates substitution of Tyr178 with more hydrophobic residues; △ indicates the retro-inverso analog; □ indicates peptide linearization; and ◆ indicates decreasing the length of cyclizing linker achieved by a thioether linkage. Solid symbols indicate a beneficial modification (i.e. improved antiviral activity and HSP70 binding), while open symbols indicate a negative effect.

<table>
<thead>
<tr>
<th>Peptide</th>
<th>IC₅₀ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV4</td>
<td>0.452</td>
</tr>
<tr>
<td>HCV10</td>
<td>0.234</td>
</tr>
<tr>
<td>HCV14</td>
<td>31</td>
</tr>
<tr>
<td>HCV15</td>
<td>0.192</td>
</tr>
<tr>
<td>HCV15R</td>
<td>3</td>
</tr>
<tr>
<td>HCV16</td>
<td>0.345</td>
</tr>
<tr>
<td>HCV18</td>
<td>0.048</td>
</tr>
<tr>
<td>HCV18RI</td>
<td>0.029</td>
</tr>
</tbody>
</table>

The IC₅₀ values for the indicated peptides. Intracellular virus production assay was performed on cells treated with the indicated peptides at a concentration range of 0.001–1000 nM. The symbols to left of the table refer to specific modifications to peptides: ▲ indicates substitution of Phe171 and/or Val173 with more hydrophobic residues; △ indicates substitution of Tyr178 with more hydrophobic residues; □ indicates peptide linearization; and ◆ indicates decreasing the length of cyclizing linker achieved by a thioether linkage. Solid symbols indicate a beneficial modification (i.e. improved antiviral activity and HSP70 binding), while open symbols indicate a negative effect.

Table 2

The dissociation constants for the indicated peptides. Constants were calculated using SPR assays conducted by injecting the indicated peptides at different concentrations onto the HSP70-bound chip. The symbols to left of the table refer to specific modifications to peptides: ▲ indicates substitution of Phe171 and/or Val173 with more hydrophobic residues; △ indicates substitution of Tyr178 with more hydrophobic residues; □ indicates peptide linearization; and ◆ indicates decreasing the length of cyclizing linker achieved by a thioether linkage. Solid symbols indicate a beneficial modification (i.e. improved antiviral activity and HSP70 binding), while open symbols indicate a negative effect.

Table 3

Fig. 2. Antiviral activity of peptides and their cytotoxicity profile. (A) Antiviral activity of peptides. Intracellular virus production assay was performed on cells treated with the indicated peptides at a concentration of 10 nM. The y axis reflects relative Renilla luciferase levels. (B) Dose response of peptides. Intracellular virus production assay was performed on cells treated with the indicated peptides at a concentration range of 0.001–1000 nM. The symbols to left of the table refer to specific modifications to peptides: ▲ indicates substitution of Phe171 and/or Val173 with more hydrophobic residues; △ indicates substitution of Tyr178 with more hydrophobic residues; □ indicates peptide linearization; and ◆ indicates decreasing the length of cyclizing linker achieved by a thioether linkage. Solid symbols indicate a beneficial modification (i.e. improved antiviral activity and HSP70 binding), while open symbols indicate a negative effect.

Fig. 2A. Antiviral activity of peptides. Intracellular virus production assay was performed on cells treated with the indicated peptides at a concentration of 10 nM. The y axis reflects relative Renilla luciferase levels. (C) Peptides are not cytotoxic. MTT assay was performed on cells treated with the indicated peptides at a concentration range of 0.001–1000 nM. The symbols to left of the table refer to specific modifications to peptides: ▲ indicates substitution of Phe171 and/or Val173 with more hydrophobic residues; △ indicates substitution of Tyr178 with more hydrophobic residues; □ indicates peptide linearization; and ◆ indicates decreasing the length of cyclizing linker achieved by a thioether linkage. Solid symbols indicate a beneficial modification (i.e. improved antiviral activity and HSP70 binding), while open symbols indicate a negative effect.

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Dissociation constant (K_d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NS5A domain I</td>
<td>3.16 × 10⁻⁷</td>
</tr>
<tr>
<td>HCV4</td>
<td>7.03 × 10⁻⁶</td>
</tr>
<tr>
<td>HCV10</td>
<td>4.23 × 10⁻⁷</td>
</tr>
<tr>
<td>HCV14</td>
<td>2.76 × 10⁻⁵</td>
</tr>
<tr>
<td>HCV15</td>
<td>2.86 × 10⁻⁷</td>
</tr>
<tr>
<td>HCV15R</td>
<td>1.13 × 10⁻⁵</td>
</tr>
<tr>
<td>HCV16</td>
<td>5.19 × 10⁻⁶</td>
</tr>
<tr>
<td>HCV18</td>
<td>8.36 × 10⁻⁷</td>
</tr>
<tr>
<td>HCV18RI</td>
<td>6.57 × 10⁻⁷</td>
</tr>
</tbody>
</table>
antiviral activity, as lipidation may be beneficial for in vivo studies (targeting the peptide to the liver and increasing the plasma half-life). Therefore, we generated the HCV6 peptide (Table 1), the palmitoylated analog of HCV5 (marked with the solid square symbol ■), and demonstrated that its antiviral activity is comparable to that of HCV5 (Table 1 and Fig. 2A).

The retro-inverso form of the hairpin peptide maintains its antiviral activity and HSP70 binding affinity

As peptides are subjected to degradation in the intracellular environment and in vivo, we sought to determine whether the retro-inverso form of the hairpin peptide would be feasible in terms of antiviral activity. We generated a retro-inverso analog of HCV18 (HCV18R) where the peptide was synthesized in reverse order and all the L-amino acids were substituted with their D-counterparts, while the D-Pro174 was changed to L-Pro. HCV18R is represented with the star ♦ symbol. In comparison with HCV18, HCV18R maintained antiviral activity (Fig. 2A), dose response (Fig. 2B and Table 2), and HSP70 binding affinity (Table 3).

Cyclization of the peptides improves their antiviral activity

We reasoned that the characteristic anti-parallel beta-sheet structure of the HBD hairpin may be important for the antiviral activity of the analog peptides. Therefore, we generated the HCV15R peptide, represented with the open diamond ○ symbol, which is linear due to the reduced disulfide bond that cyclizes the peptide (Table 1). As shown in Fig. 2A, linearization of the peptide reduced its antiviral activity with the cyclized form being more effective than the linear form. Furthermore, the dose response of HCV15R (IC_{50} ~ 3 nM) was significantly reduced compared to HCV15 (IC_{50} ~ 0.192 nM) (Fig. 2B and Table 2). Linearization of the peptide also decreased the binding affinity of HCV15R to HSP70 compared with HCV15 and HCV4 (Table 3).

Linearization of the peptide may reduce the efficacy of the peptide by eliminating the optimal hairpin-like conformation of the peptide and/or decreasing its half-life as linear peptides may be more susceptible to enzymatic degradation. We synthesized all peptide analogs used in this study (except HCV15R) with a cyclizing linker.

Decreasing the length of the cyclizing linker in peptides lowers their antiviral activity

The majority of the peptide analogs used in this study were cyclized by a disulfide linker to achieve the hairpin-like structural conformation observed in the crystal structure (Tellingshuijen et al., 2005) (Fig. 1). To determine if altering the length of the linker would affect the efficacy of the peptide, we synthesized an analog of the HCV15 peptide (HCV16, marked with the open square ○ symbol) in which the disulfide linker is replaced by the shorter S-carboxymethyl-linker, obtained by substituting the N-terminal cysteine with a chloroacetyl group and subsequent intramolecular S-alkylation (Table 1). Decreasing the linker length negatively impacted the antiviral efficacy of the peptide (Fig. 2A). The IC_{50} of the peptide also increased from 0.192 nM (HCV15) to 0.345 nM (HCV16) (Table 2). This may indicate that the binding of the HBD hairpin is highly optimized in the binding pocket and that minute structural changes may affect its conformation effectively decreasing the peptide binding affinity. Thus, we tested the HSP70 binding affinity of HCV16 and found that its dissociation constant was higher than that of HCV15 (Table 3).

Hairpin peptide analogs do not display cytotoxic effects

To ensure that the antiviral activity of the peptides in the HCVcc system is not affected by their potential cytotoxic effects, MTT assays were performed at a concentration range of 10 nM–10 μM for 72 h of treatment. As shown in Fig. 2C, no significant cytotoxicity was observed at the 10 μM concentration after 72 h of peptide treatment.

Secondary structure analysis of HCV peptides by Fourier transform infrared (FTIR) spectroscopy demonstrates a predominant beta-sheet structure

We proceeded to determine the secondary structure of the HCV suite of peptides in aqueous solvent systems using FTIR spectroscopy. The results of FTIR spectral analyses are shown in Fig. 3A and B, and the results of the deconvolution of the spectra are shown in Table 4. In aqueous buffer, all of the HCV peptides have a dominant beta-sheet structure (Table 4). The parental peptide HCV1 has a secondary structure in aqueous buffer that is anti-parallel beta-sheet with a major peak centered around 1625 cm⁻¹ and a minor signature band at 1690 cm⁻¹ (Fig. 3A) that is similar to the conformation observed in the crystal structure of NS5A domain I (Tellingshuijen et al., 2005). In contrast to the spectrum of HCV1, all other HCV variants have a broader spectrum centered from 1630 to 1638 cm⁻¹, and that is more typical of peptides assuming mostly parallel beta-sheet conformations (Fig. 3A and B). Overall, the deconvolution results suggest that all peptides have largely beta-sheet structure followed by turn and disordered conformations in aqueous environments. There were only minor contributions for alpha helical conformations with the most notable amount for the reduced form of the peptide (HCV15R) (Table 4). Further, the contribution of turns is lowest for HCV15R. These observations are consistent with our findings above that the HCV15R peptide (with reduced disulfide bond) displays a significant decrease in antiviral activity and HSP70 binding affinity (Fig. 2A and Tables 2 and 3).

^{13}C-enhanced FTIR spectroscopy of HCV3 peptide indicates a secondary structure consisting of an N terminal beta-sheet followed by a turn and a C terminal beta-sheet

To gain further insights into the residue specific structure of the HCV variants, we isotopically enhanced HCV3 residues with^{13}C carbonyl labels for selective amino acids in the N-terminal, mid-sequence, and C-terminal domains (Dwivedi and Krimm, 1984; Tadesse et al., 1991). The spectra for the selectively labeled sequences are shown in Fig. 3C. When HCV3 peptide was enhanced with^{13}C labels at Phe at position 3 (Phe171) and Val at position 5 (Val173), there was a characteristic shift of 37 wavenumbers from 1635 cm⁻¹ to 1598 cm⁻¹ indicative of these residues assuming parallel beta-sheet conformations (Fig. 3C, spectrum HCV3a). Spectra of the mid-sequence^{13}C carbonyl labels at Gly at position 6 (Gly174) and Leu at position 7 (Leu175) also showed a spectral down shift from 1649 cm⁻¹ to 1612 cm⁻¹ typical of residues participating in Type III beta-turn (310 helix) conformations when in deuterated buffer (Byler and Susi, 1986) (Fig. 3C, spectrum HCV3b). When the Tyr at position 10 (Tyr178) was enhanced with^{13}C, there was also a shift from the beta-sheet region of the unlabeled parent FTIR spectra centered in the 1632 cm⁻¹ absorbance to 1695 cm⁻¹ suggesting that this residue was also assuming mostly parallel beta-sheet conformations (Fig. 3C, spectrum HCV3c).

Molecular simulation confirms a beta-hairpin secondary structure for HCV3 peptide

Based on the above^{13}C labeled residue assignments obtained by isotope enhanced FTIR measurements, a highly accurate model
of HCV3 in water was then determined using molecular dynamics refinement. This was facilitated by conformationally constraining the labeled residue while allowing the remaining residues to assume conformations indicative of an equilibrium conformation in a simulated water environment. As shown in Fig. 4A and B, the HCV3 peptide backbone rapidly reached a stable equilibrium secondary conformation within the first few nanoseconds of simulation. Based on the molecular dynamics refinement, the residue-specific secondary structure of HCV3 is diagramed in Fig. 4C. The sequential map indicates that the disulfide linked Cys1 and Cys12 have a random or disordered conformation while the beta-sheet components flank a well-defined turn element that includes Gly6 and Leu7. There are two beta-sheet components one from Ser2 to Val5 and the other from His8 to Pro11. The beta-sheets assume mostly parallel conformations and are configured with the turn to form a beta-hairpin structure (Fig. 5A) which is remarkably similar to the HBD moiety from the crystal structure (Tellinghuisen et al., 2005) (Fig. 5B). This overall structure has an amphipathic character with amino acids on one side of the beta-hairpin being polar residues and the other side bearing amino acids with hydrophobic side chains. There are also two intra-chain components that stabilize the parallel beta-hairpin format along with the disulfide linkage between Cys1 and Cys12. One element is the salt bridge between Arg4 and Glu9. The existence of this ion-lock is confirmed by the fact that the distance between the side-chain charged group centroids is maintained during the simulation to be within the 4 angstrom distance typical of most salt-bridges in proteins (Kumar and Nussinov, 1999). A second non-covalent side chain interaction that potentially adds to the stability of the

Table 4

Proportions of secondary structure9 for HCV peptides8 in deuterated phosphate buffer as estimated from Fourier self-deconvolution of the FTIR spectra6 of the peptide amide I band.

<table>
<thead>
<tr>
<th>Peptide</th>
<th>% Conformation</th>
<th>α-Helix</th>
<th>β-Sheet</th>
<th>Turn</th>
<th>Disordered</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV1</td>
<td>2.10</td>
<td>43.11</td>
<td>31.05</td>
<td>23.74</td>
<td></td>
</tr>
<tr>
<td>HCV2</td>
<td>4.66</td>
<td>53.56</td>
<td>28.94</td>
<td>17.84</td>
<td></td>
</tr>
<tr>
<td>HCV3</td>
<td>11.60</td>
<td>54.34</td>
<td>21.96</td>
<td>12.04</td>
<td></td>
</tr>
<tr>
<td>HCV4</td>
<td>11.86</td>
<td>41.48</td>
<td>29.21</td>
<td>17.45</td>
<td></td>
</tr>
<tr>
<td>HCV5</td>
<td>10.55</td>
<td>50.90</td>
<td>25.72</td>
<td>12.83</td>
<td></td>
</tr>
<tr>
<td>HCV6</td>
<td>12.34</td>
<td>52.87</td>
<td>20.39</td>
<td>14.40</td>
<td></td>
</tr>
<tr>
<td>HCV15</td>
<td>11.05</td>
<td>39.52</td>
<td>31.46</td>
<td>17.97</td>
<td></td>
</tr>
<tr>
<td>HCV15R</td>
<td>24.77</td>
<td>49.12</td>
<td>12.97</td>
<td>13.14</td>
<td></td>
</tr>
<tr>
<td>HCV16</td>
<td>14.68</td>
<td>40.36</td>
<td>18.71</td>
<td>26.25</td>
<td></td>
</tr>
<tr>
<td>HCV18</td>
<td>5.88</td>
<td>47.91</td>
<td>29.74</td>
<td>16.47</td>
<td></td>
</tr>
<tr>
<td>HCV18R</td>
<td>7.82</td>
<td>53.88</td>
<td>22.55</td>
<td>15.75</td>
<td></td>
</tr>
</tbody>
</table>

9 Data are the means of four separate determinations and have an SE ± 5% or better.
8 HCV Peptide (i.e., 2 mM HCV) desolvated in deuterated 10 mM phosphate buffer pH 5.6 (Fig. 3).
6 FTIR spectra were deconvoluted as described in Materials and methods.

Fig. 3. FTIR spectroscopy analyses of HCV peptides. (A, B) FTIR spectral analysis of unlabeled HCV peptide secondary structure in deuterated 10 mM phosphate buffer pH 5.6. (C) FTIR spectral analysis of HCV3 13C isotope enhanced peptide secondary structure in deuterated 10 mM phosphate buffer pH 5.6. HCV3 is unlabeled peptide; HCV3a is isotope-enhanced at residues Phe3 and Val5; HCV3b is isotope-enhanced at Gly6 and Leu7; and HCV3c is isotope-enhanced at Tyr10.
beta-hairpin structure is the interaction between Phe3 and Tyr10. This Phe-Tyr aromatic pair maintains Cα–Cα distances over the time course of the molecular dynamics run that favor π-stacking and T-shape orientations for possible interactions that enhance intra-chain stability of the hair-pin structure (Chelli et al., 2002; McGaughey et al., 1998).

Discussion

In this study, we have characterized the interaction of the NS5A HBD with HSP70, identified the amino acid residues involved in the NS5A/HSP70 interaction, and developed peptides that are more efficacious than HCV4 in binding HSP70 and in blocking virus production.

As reported previously, the HBD-mediated NS5A/HSP70 interaction is involved in the NS5A-driven IRES-mediated translation of the viral genome, and treatment of cells with the peptides corresponding to HBD significantly inhibits IRES-mediated translation (Khachatoorian et al., 2012b). Furthermore, knockdown of HSP70 was shown by our group and others to significantly reduce viral IRES-mediated translation and protein production (Gonzalez et al., 2009; Lim et al., 2012). These and our current results indicate that the NS5A/HSP70 interaction is critical for viral proliferation. Recently, we also analyzed the binding of heat shock cognate protein (HSC) 70 with NS5A and found that NS5A and HSC70 directly bind each other as well (Khachatoorian et al., 2014). Nonetheless, our data as well as another report indicated that HSC70 is involved in infectious virion assembly rather than IRES-mediated translation (Khachatoorian et al., 2014; Parent et al., 2009). We also showed that the compensatory upregulation of HSP70 due to knockdown of HSC70 fails to improve infectious virion assembly and that simultaneous knockdown of HSP70 and HSC70 leads to a similar decrease in viral translation as knockdown of HSP70 alone further supporting the distinct roles that HSP70 and HSC70 play in the viral life cycle. We are currently investigating the NS5A/HSC70 interaction biochemically to identify the precise site(s) of interaction on both proteins. It may be possible that HSC70 also utilizes the HBD hairpin to bind to NS5A.

We hypothesized that the amino acid residues within the HBD hairpin that are critical for the NS5A/HSP70 interaction should...
most likely be conserved, and sequence comparison confirmed the existence of five conserved residues in the hairpin: Phe171, Val173, Gly174, Leu175, and Tyr178. Analysis of the previously reported crystal structure of dimeric NS5A domain I (Tellinghuisen et al., 2005) readily revealed that Phe171, Val173, and Tyr178 occur on one side of the plane of the hairpin beta-sheets suggesting that they could form a binding surface with HSP70. In addition, the crystal structure also shows the HBD and these three residues to be on the surface of the dimer and exposed supporting their role as the NS5A/HSP70 binding interface. In an alternate crystal structure of dimeric NS5A domain I (Love et al., 2009), the two subunits appear as more compact closing the proposed RNA binding cleft (Fig. 6). In this structure, while the two HBD moieties appear to be still exposed, their location changes from the side of the molecule to the bottom (Fig. 6). It is possible that the former crystal structure provides for a better conformation for the HBD to bind HSP70. Nevertheless, NS5A likely needs to undergo a conformational change to allow HBD to form a tight binding interface with HSP70, and this may be possible in both crystal structure conformations.

To verify that these three conserved residues are involved in the NS5A/HSP70 interaction, we substituted them with artificial amino acids with large hydrophobic side chains. Substitutions at Phe171 and Val173 improved the antiviral activity and binding affinity of the peptide, whereas substitution of Tyr178 had the opposite effect. This is expected as tyrosine is a polar amino acid. In addition substitution of the other non-conserved amino acids within the hairpin did not affect cellular entry, antiviral activity, and binding affinity of the peptide. Thus, we conclude that the binding of NS5A with HSP70 is mediated by these three conserved amino acids within the C34 hairpin.

To confirm our structural predictions of the peptide in aqueous environments, we performed FTIR spectroscopy on the majority of the peptides generated and observed that all peptides primarily consist of beta-sheets and beta-turns consistent with the crystal structure of the hairpin in the NS5A domain I (Tellinghuisen et al., 2005). Alpha-helical contributions were minor except for the linearized HCV15R peptide which also shows significantly reduced antiviral activity and HSP70 binding affinity. FTIR spectroscopy also indicated the existence of turn element in the peptide consistent with our analysis of the crystal structures. Furthermore, 13C-enhanced spectroscopy of the HCV3 peptide clearly demonstrated that Gly174 and Leu175 form a turn element between the two beta-sheets of the hairpin confirming our original predictions. Molecular simulation of the HCV3 FTIR spectral analyses further confirmed the existence of all the predicted elements of the peptide secondary structure including the N and C terminal beta-sheets flanking a beta-turn.

Thus, we have confirmed the antiviral activity of a number of HIPs that bind HSP70 and block the NS5A/HSP70 interaction. Considering that most available therapeutic agents target the viral proteins and induce the generation of resistant viral strains, HIPs may serve as a potential new class of therapeutics for HCV infection by targeting the host HSP70 as opposed to viral proteins in order to minimize the development of resistance. Our data indicates that the antiviral activity of HIPs is comparable to that of sofosbuvir and ledipasvir in the HCVcc system (Lawitz et al., 2012; Soﬁa et al., 2010). In combination with DAAs, HIPs may further be able to dispense with the need for PEG-IFN and RBV that are currently utilized in combination therapies. Further, insight provided here may also allow for development of therapies for others viruses that utilize HSP70 recruitment.

Materials and methods

Plasmid constructs

NS5A domain I was cloned in the pET-28b plasmid (Novagen, 69865-3). The HCV IRES reporter plasmid has been previously described (Gonzalez et al., 2009). An intra-genotype 2 chimeric monocistronic reporter virus pNRLFC based on pJ6/JFH-C parental virus has been described previously (Arumugaswami et al., 2008).
For the current study, we have used a chemically synthesized plasmid pFNX-RLuc (having similar sequences to pNRLFC) for construction of recombinant virus.

Peptide synthesis and characterization

Peptides were synthesized by the solid phase method using a CEM Liberty automatic microwave peptide synthesizer (CEM Corporation), applying 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry (Fields and Noble, 1990) and standard, commercially available amino acid derivatives and reagents (EMD Biosciences and ChemImpex International). Rink Amide MBHA resin (EMD Biosciences) was used as a solid support. Peptides were cleaved from resin using modified reagent K (TFA 94% (v/v); phenol, 2% (w/v); water, 2% (v/v); TIS, 1% (v/v); EDT, 1% (v/v); 2 h) and precipitated by addition of ice-cold diethyl ether. Reduced peptides were purified by preparative reverse-phase high performance liquid chromatography (RP-HPLC) and their purity evaluated by matrix-assisted laser desorption ionization spectrometry (MALDI-MS) as well as by analytical RP-HPLC. Disulfide bond formation: Peptides were dissolved at a final concentration of 0.25 mg/ml in 50% DMSO:H2O and stirred overnight at room temperature. Subsequently peptides were lyophilized and re-purified on a preparative C18 SymmetryShield™ RP-HPLC column to >95% homogeneity. Their purity was evaluated by MALDI-MS as well as by analytical RP-HPLC. Analytical RP-HPLC: Analytical RP-HPLC was performed on a Varian ProStar 210 HPLC system equipped with ProStar 325 Dual Wavelength UV–vis detector with wavelengths set at 220 nm and 280 nm (Varian Inc.). Mobile phases consisted of solvent A, 0.1% TFA in water, and solvent B, 0.1% TFA in acetonitrile. Analyses of peptides were performed with an analytical reversed-phase C18 SymmetryShield™ RP18 column, 4.6 × 250 mm², 5 µm (Waters Corp.) applying linear gradient of solvent B from 0% to 100% over 100 min (flow rate: 1 ml/min).

Cell culture

The cell line huh-7.5 was maintained in a humidified atmosphere containing 5% CO₂ at 37 °C in Dulbecco’s Modified Eagle Medium (Mediatech, 10-013-CM) supplemented with 10% fetal bovine serum (Omega Scientific, FB-01) and 2 mM L-Gln (Life Technologies, 25030). Huh-7.5 cells were a kind gift from Charles Rice (The Rockefeller University, New York, NY).

Cell viability

Cell viability was determined using MTT Cell Proliferation assay (ATCC, 30-1010K) according to manufacturer’s instructions.

Infectious virus production

pFNX-RLuc was in vitro transcribed, and the purified RNA was electroporated into huh-7.5 cells to generate infectious viral supernatant as previously described (Arumugaswami et al., 2008).

Viral assays

The HCV reporter virus was utilized as described previously (Khachatourian et al., 2012a). All infection assays were performed with a viral titer of 10⁷ focus forming units and a multiplicity of infection (MOI) of 0.1. Intracellular virus production: Huh-7.5 cells were infected for 3 h at which point the medium was replaced, indicated peptides were added, and infection was allowed to proceed. Cells were harvested 48 h later, and luciferase activity was measured using the Renilla Luciferase Assay System (Promega, E2820).

Production and purification of recombinant proteins

NSSA domain I was expressed and purified as described previously (Wheatley et al., 2013). Briefly, protein expression was induced with 1 mM IPTG in BL21(DE3) Escherichia coli cells, shaking at 250 rpm, for 5 h at 37 °C. Cells were centrifuged for 5 min at 6000 rpm and stored at −20 °C. Cells were resuspended in 50 mM Tris–HCl pH 7.6, 300 mM NaCl, and 20 mM imidazole, with Protease Inhibitor Cocktail (Sigma-Aldrich, P8849-5ml) and lysed by sonication. Cells were spun down in a rotor SS-34 at 16,500 rpm for 30 min, filtered through a 0.2 µm filter, and applied to a Hi-trap Nickel column by a syringe at room temperature. Proteins were eluted in one step with 50 mM Tris–HCl pH 7.6, 300 mM NaCl, and 400 mM imidazole.

Surface plasmon resonance (SPR)

Binding studies were performed on a Biacore 3000 instrument (Biacore AB, Uppsala, Sweden). Proteins were immobilized on CM5 sensor chips by amine coupling. The solution phase analytes were dissolved in HBS-EP buffer, which contained 0.15 M NaCl, 10 mM HEPES, pH 7.4, 3 µM EDTA, and 0.005% polysorbate 20. The solutions traversed the sensors at a flow rate of 50 µl/min. Costar low-retention polypropylene tubes (Corning, 3207) were used throughout. Binding results were expressed in resonance units. Kinetics and dissociation constants were analyzed and calculated with BIAevaluation Software Version 4.1.

Fourier transform infrared (FTIR) spectroscopy

Infrared spectra were recorded at 25 °C using a Bruker Vector 22™ FTIR spectrometer with a deuterated triglycine sulfate (DTGS) detector, and averaged over 256 scans at a gain of 4 with a resolution of 2 cm⁻¹. Peptide samples were initially freeze-dried several times from 10 mM HCl in D₂O to remove any interfering counterions and residual H₂O. Solution spectra of peptides were made in deuterated 10 mM phosphate buffer, pH 5.6 (pD = pH + 0.4). The spectra were acquired at a peptide concentration of 2 mM in deuterium buffer using a temperature controlled, demountable liquid cell with calcium fluoride windows fitted with a 50 µm thick Mylar spacer (Harrick Scientific, Pleasantville, NY). The relative proportions of α-helix, turn, β-sheet, and disordered conformations of solution and multilayer IR spectra were determined by Fourier self-deconvolution for band narrowing and area calculations of component peaks of the FTIR spectra using curve-fitting software supplied by Galactic Software (GRAMS/AL, version 8.0; Thermo Electron Corp., Waltham, MA). The frequency limits for the different structures were α-helix (1662–1645 cm⁻¹), β-sheet (1637–1613 and 1710–1682 cm⁻¹), turns (1682–1662 cm⁻¹), and disordered or random (1650–1637 cm⁻¹) (Byler and Sust, 1986).

Molecular Structure Simulation of HCV3 in Aqueous Solution

A starting structure for the HCV3 peptide amino acid sequence was approximated by using Hyperchem 8.0 (http://www.hyper.com) to template the backbone structure of the beta-hairpin conformation that was derived from the homologous segment of the crystal structure of NS5A domain I (PDB 12H1, residues (173–184) (Tellinghusien et al., 2005). This preliminary structure was placed in a periodic 56 Å² box of TIP4P water, and the ensemble was neutralized with counterions to simulate the environment used for the FTIR isotope enhanced experimental measurements. The peptide in the solution box was conjugate-gradient minimized using the Polak–Ribiere approach implemented in Hyperchem. This minimized HCV3 aqueous ensemble was then ported to the Gromacs program suite, version 4.5.5 (http://www.gromacs.org), and subjected to the steepest
descent method using the Amber03 force field option (Hess et al., 2008).

The steepest descent minimized system was further subjected to 40 ps of pre-run molecular dynamics at 300 K to allow the solvent to equilibrate while restraining the peptide. After pre-run solvent equilibration the peptide structure was further refined by 300 ns of MD simulation at 300 K with residue specific constraints based on FTIR isotope enhanced experimental observations. The Berendsen protocol was used for temperature and pressure coupling and the Particle Mesh Ewald method was employed for evaluating long-range electrostatic interactions. The time-dependent evolution of the secondary structure (analyzed using the DSSP criteria (Kabsch and Sander, 1983)) for the peptide in the water environment indicated when equilibrium was reached. Molecular model calculations were rendered using PyMOL v0.99 (http://www.pymol.org).

Crystal structure analysis

The illustrations for crystal structures 1ZHI and 3FOQ were rendered using UCSF Chimera v1.9 (http://www.cgl.ucsf.edu/chimera).

Statistical analysis

Error bars reflect the standard deviation. P values were determined by Student t test. All viral assays were done with six biological replicates for each individual assay.

IC50 calculation

IC50 values were calculated based on the formula derived from a third degree polynomial curve fit in Microsoft™ Excel™.

Financial support

This work was supported by NIH under Grant nos. R01DK090794 to SWF and R21AI084090 to AD and also supported by California Center for Antiviral Drug Discovery Grant University of California Office of the President, MRPI # 143226 to AD.

Acknowledgments

The authors thank David Dawson for helpful discussions and Charles Rice for providing huh-7.5 cells.

References

Baron, S., 1996. Medical Microbiology, 4th ed. University of Texas Medical Branch at Galveston, Galveston, TX.